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dian8.00) at baseline. Results differed according to countries, with a mean of 12.13
(SD5.17,Median11.00) in France, 9.32 (SD4.17,Median8.00) inGermany and 8.00
(SD3.89,Median7.00) inUK.About 30%of those identified at baseline still hadCDat
6, 12, 18 and 24months. Patients with CDwere found to havemore severe symptoms
(PANSS 67.7 vs. 42.5 p0.0001), a lower QoL (EQ-5D index score: 0.71 vs. 0.77 p0.001),
lower functioning (GAF: 45.9 vs. 59.0 p0.001), more severe side effects (SSES: 0.74 vs.
0.66 p0.03) and to be more depressed (CDSS: 3.09 vs. 2.55 p0.001). Results were
consistent within countries. CONCLUSIONS: Our study suggests that patients with
CD form a stable population overtime with higher clinical burden. Research on the
cognitive impairment of schizophrenia is of key importance in schizophrenia,more so
even than positive or negative symptoms.
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FUNCTIONAL OUTCOME MEASURES: A POWERFUL TOOL TO DEMONSTRATE
TREATMENT SUCCESS IN SCHIZOPHRENIA
Chung D, Guan Q, Rizzo M
Double Helix Consulting Group, New York, NY, USA
OBJECTIVES:Most antipsychotics were developed with the goal of addressing psy-
chopathology symptoms and maintaining the stability of patients. With the num-
ber of antipsychotics in the market, a paradigm shift instead of therapy evolution
will be the key to product success. Maintenance therapy will be inadequate and
new antipsychotics will have to demonstrate improvement in symptom remis-
sions and recovery, which can be validated by the ability to live and function
independently. The objective of this study is to evaluate similarities and differ-
ences between instruments that assess functional outcomes, to evaluate func-
tional outcome endpoints validated by newer atypicals and to understand how
these endpoints increase the value perception of a new antipsychotic.METHODS:
An online literature search was conducted to identify instruments and functional
domainsmeasured. Current atypicalswere evaluated for functional endpoint stud-
ies measured. Primary research was conducted with five payers from plans with
managed Medicaid to understand how functional outcome measures influence
their value perception. RESULTS: Twelve different instruments were cross ana-
lyzed for eighteen functional domain measurements. Our analysis show that the
most common functional domains measured are ability to form extended social
relationships (n92%), self-care (n75%), and occupational improvement (n67%)
while only two instruments measured life satisfaction, vitality, communication,
recreation, and public safety. Among the current atypicals, paliperidone included
functional outcome endpoints using the PSP scale to demonstrate efficacy. Payers
interviewed also stated that demonstrating functional improvements and ability to
translate this to daily living would be a key factor in justifying value and obtaining
favorable access for new antipsychotics. CONCLUSIONS:With a variety of instru-
ments available and the vast combination of possible functional domain endpoints
that can be measured, choosing an instrument that is objective, reliable, easily
administered and simple but comprehensive enough to measure impact in daily
function would be a powerful tool to demonstrate successful treatment.
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OBJECTIVES: Antipsychotic polypharmacy is frequently used in schizophrenia al-
though the incremental effect for relapse prevention is uncertain. The purpose of
this study is to compare risks of relapse between polypharmacy andmonotherapy
based on an observational study. Propensity score matching (PSM) and a latent
variable model (LVM) were used to correct for selection bias.METHODS: Analyses
were based on data from a multinational prospective cohort study that enrolled
1208 patients, followed over 2 years (EuroSC). The effect of treatment (combination
therapy vs. monotherapy) on the risk of relapse was estimated using Cox models.
PSMwas used to create two comparable groups of patients. Propensity scores were
derived from 11 variables measuring disease severity, quality of life, depression
and functioning at baseline. A LVMwas used to account for bias related to unmea-
sured confounding factors. It consisted of two parts estimated simultaneously: a
logisticmodel predicting treatment choice and a Coxmodel on time to relapse. The
model assumed that an unmeasured factor affecting risk of relapse was taken into
account in the choice of treatment. All analyses were performed in a Bayesian
framework, usingWinBugs. RESULTS:Matched groups each included 344 patients,
with relapse rates of 51% for monotherapy and 59% for polypharmacy. The hazard
ratio for relapse with monotherapy versus polypharmacy was 0.77 (95% CI: 0.63,
0.94) based on the simple Cox model and 1.34 (0.87, 2.39) based on LVM. The LVM
was better according to the Deviance Information Criterion. CONCLUSIONS: Re-
sults of the LVM suggest that polypharmacy is associated with a reduced risk of
relapse, and contradict results based on PSM ignoring bias related to unmeasured
confounding factors. The LVMappears to be a usefulmethod to detect unmeasured
confounding. Further research on the specification of latent variables is recom-
mended to accurately quantify treatment effects.
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OBJECTIVES: The purpose of this study is to: 1) characterize the changes in utiliza-
tion of psychotropicmedications among adults with anxiety disorder over a 6-year
period (2004-2009), and 2) identify factors associatedwith psychotropicmedication
use. METHODS: Patients with anxiety disorder were identified in the 2004 to 2009
Medical Expenditure Panel Survey (MEPS). Psychotropic medication use was ascer-
tained from a self-reported prescription file. The number and percentage of pa-
tients with anxiety using a psychotropic medication was calculated for each year
and drug class. We used t-tests to compare psychotropic medication use between
2004 and 2009, and a logistic regression model to identify the factors associated
with psychotropic medication use. RESULTS: The estimated number of adult pa-
tients who reported having an anxiety disorder increased from 18.9 million in 2004
to 21.4 million in 2009. The percentage of patients who reported ever using a psy-
chotropic medication grew from 62.5% in 2004 to 68.6% in 2009 (p0.05) and over
one-third of patients reported ever using a selective serotonin reuptake inhibitors
(SSRI) (35.3% in 2004 to 37.1% in 2009). From 2004 to 2009, there was a significant
increase in the use of benzodiazepines (26.1% to 32.9%, p0.01), serotonin-norepi-
nephrine reuptake inhibitors (SNRI) (6.5% - 10.5%, p0.01), and atypical antipsy-
chotics (4.8% to 8.4%, p0.01). A higher prevalence and significant increase in the
use of benzodiazepines was observed among older adults aged 65 years (43.9% in
2004 - 53.0% in 2009, p0.01). Multivariate logistic regression results showed that
white race, female gender, higher education, private insurance, and comorbid
mood disorders were associated with self-reported psychotropic medication use.
CONCLUSIONS: In the US, psychotropic medication use among patients with anx-
iety increased from 2004 to 2009. The high prevalence and increasing trend of
benzodiazepine use among older patients with anxiety disorder needs more re-
search to evaluate its implications.
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A REAL-WORLD US RETROSPECTIVE DATABASE ANALYSIS EVALUATING
TREATMENT PATTERNS, HEALTH CARE RESOURCE UTILIZATION AND COSTS
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OBJECTIVES: Compare treatment patterns, health care resource utilization and
costs in patients with bipolar disorder newly treated with quetiapine IR (QTP-IR) or
XR (QTP-XR).METHODS: An observational, retrospective cohort study utilizing the
HealthCore Integrated Research Database identified patients (18 - 64 years) with an
ICD-9 diagnosis of bipolar disorder and 1 pharmacy claim for QTP-IR or QTP-XR
between October 2, 2008 and July 31, 2010. Outcomes included: patient character-
istics at the index date (first claim for QTP-IR/QTP-XR); 12-month pre-index clinical
characteristics, health care resource utilization and costs (inpatient, outpatient
and ER visits; pharmacy and other costs); 12-month post-index treatment patterns,
health care resource utilization and costs, assessed using generalized linear mod-
els adjusted for multiple variables. RESULTS: A total of 3049 patients with bipolar
disorder were analyzed (QTP-IR, n2,398; QTP-XR, n651). Prior to initiation of
QTP, the cohorts had some different characteristics, which were adjusted for. Pa-
tients initiating treatment with QTP-XR were more likely to have no change or
discontinuation of their index therapy (8.8% vs. 5.7%; OR 1.44 [95% CI 1.03, 2.00],
p0.05) comparedwith QTP-IR. The average daily dose (ADD;mean) of QTP-XRwas
higher than QTP-IR (225 mg/day vs 175 mg/day, p0.0001). An ADD of 300-800 mg
was reached sooner (15.6 days vs. 30.8 days, p0.01) and inmore patients (44.2% vs.
27.2%, p0.0001) initiated with QTP-XR compared with QTP-IR. There were no dif-
ferences in total healthcare costs between cohorts; however, patients initiated
with QTP-XR were less likely to be hospitalized for mental-health related reasons
(OR 0.65 [95% CI 0.50, 0.85], p0.01), and incurred lowermental-health related costs
($6686 vs. $7577, p0.01), compared with QTP-IR. CONCLUSIONS: Treatment pat-
terns and dosing differed in patients with bipolar disorder treated with QTP-XR
compared with QTP-IR in real-world practice. Mental-health related hospitaliza-
tions and costs were reduced in the 12 months following patients initiating treat-
ment with QTP-XR compared with QTP-IR.
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OBJECTIVES:AttentionDeficit/HyperactivityDisorder (ADHD) is oneof themost com-
monly diagnosed behavioral disorder among children. Main goal of the treatment of
ADHD is to reduce the symptoms of ADHD and improve physical and mental func-
tioning. Different factors affect utilization of ambulatory care by ADHD patients. Our
knowledge of these factors, however, is limited. This study tries to fill this gap. Results
from this study can help in identifying factors that might be helpful in reducing dis-
parity in ambulatory care received by ADHD patients. METHODS: This study used
data from 2003-2008 Medical Expenditure Panel Survey (MEPS). Sample consisted of
patients with ADHD who were identified using International Classification of Dis-
eases, ninth revision, Clinical Modification (ICD-9-CM) codes. Independent variables
were selected based on previous studies in the area of ambulatory visits utilization.
Negative binomial regression at a 5% significance level was conducted to estimate the
relationship betweenpatient characteristics andnumber of patient’s visit to the office
based physicians. RESULTS: Prevalence of ADHD was 1.59% (n28,355,049). Most of
the patients were male (66.57%), less than/equal to17 years old (66.14%), White
(84.16%), and had private health insurance (65%). Females had 1.28 times (Incidence
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Rate Ratio (IRR) - 1.28, 95% CI:1.09 -1.51) higher rate for number of visits to the office
basedphysicianswhencompared tomales. Blackshad31% (IRR-0.69, 95%CI:0.53-0.89)
lower rate of ambulatory care utilization when compared toWhites. Publicly insured
individuals had 66% (IRR-1.66, 95%CI:1.26-2.18) higher rate of ambulatory care utiliza-
tionwhereas uninsured individuals have 37% (IRR-0.63, 95%CI:0.40-0.99) lower rate of
ambulatory care utilization than the ADHD patients with private health insurance.
CONCLUSIONS: Gender, and racial disparities exist in ambulatory care utilization
among ADHD patients. Providing some kind of health insurance coveragemight help
in reducing thesedisparities andoptimizingambulatory careutilizationamongADHD
patients.
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OBJECTIVES: ADHD is a major concern since it is one of the most commonmental
disorders affecting children and adolescents. The prevalence of ADHD has been
reported to be increasing in the past decade. We assessed the trends in prevalence
of ADHD drug use in the Netherlands from 2000 until 2010. METHODS: From the
PHARMO database, including amongst others, drug dispensing records of approx-
imately 3.2 million inhabitants in The Netherlands, we selected patients with at
least one dispensing of ADHDmedication includingmethylphenidate, dexamphet-
amine and atomoxetine, between 2000 and 2010. For each calendar year, patients
were counted as prevalent ADHDdrug users if they received a dispensing for ADHD
treatment in the respective calendar year. The number of ADHD drug users in
PHARMOwas divided by the number of residents in PHARMO andmultiplied by the
number of inhabitants in the Netherlands, standardized for age and gender. Re-
sults were stratified by age groups and gender. RESULTS: The prevalence of ADHD
drug treatment among males was higher than among femals. From 2000 to 2010,
the prevalence among children (0-12 years) has increased 2.6-fold in males (from
158 to 410 per 10,000) and 4.5-fold in females (from 27 - 119 per 10,000). The prev-
alence among adolescents (13-18 years) has increased 4.0-fold in males (170 - 675
per 10,000) and 7.4-fold in females (27 - 200 per 10,000). The prevalence among
adults (19 years) has increased 8.2-fold in males (from 8 - 63 per 10,000) and
10.1-fold in females (from 4 - 43 per 10,000). CONCLUSIONS: This study provides a
comprehensive overview of trends in prevalence of ADHD drug treatment in The
Netherlands. Both in males and females, a continuous increase in prevalence was
observed.
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OBJECTIVES: ADHD has become a much debated topic in the last few years. More
attention and awareness for ADHD has led to an increase in incidence. Especially
awareness for the subtype of ADHD where patients, mostly females, demonstrate
predominantly inattentive symptoms, has increased. We determined the male/
female incidence ratio of ADHD drug treatment in the Netherlands from 2000 until
2010. METHODS: From the PHARMO database, including amongst others, drug
dispensing records of approximately 3.2million inhabitants in theNetherlands, we
selected patients with a first dispensing of ADHD medication including methyl-
phenidate, atomoxetine and dexamphetamine in the period 2000-2010. For each
calendar year, the male/female incidence ratio of ADHD drug use was determined
by dividing the incidence among males by the incidence among females. Results
were stratified by age groups. RESULTS:Overall, themale/female incidence ratio of
ADHD drug treatment decreased from 3.4:1 in 2000 to 1.6:1 in 2010, meaning a
growing proportion of female patients. The largest decrease in the male/female
ratio was observed among adolescents (13-18 years: from 4.5:1 in 2000 to 1.6:1 in
2010), followed by 9-12 year-olds (from5.5:1 in 2000 - 2.7:1 in 2010) and 0-8 year-olds
(from 6.2:1 in 2000 - 3.5:1 in 2010). Among adults and seniors this ratio fluctuated
from 0.9:1 to 2.1:1. Although the incidence among females has increasedmore over
the years, the incidence among males remained higher throughout the study
period. CONCLUSIONS: This study shows that the proportion of female patients
starting ADHD drug treatment is increasing. This in line with the increased aware-
ness of ADHD among females.
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OBJECTIVES: To examine the association between obesity and depression/anxiety
and related expenditures in children and adolescents.METHODS: Data from Med-
ical Expenditure Panel Survey (MEPS) longitudinal panels 9, 10, 11 and 12 were
combined to analyze the risk of depression/anxiety in a cohort of children and
adolescents (aged 6-17 years). Incident depression/anxiety was identified during
one year follow-up using Clinical Classification Codes (CCCODEX) for depression
(657) and anxiety (651) or by Multum Lexicon Therapeutic Classification Codes for
anti-anxiety (067) or antidepressant (249) drugs. Body Mass Index (BMI)-for-age 
85th-percentile of the 2000 sex-specific Center for Disease Control (CDC) BMI-for-
age growth charts, was considered obese/overweight. Due to possibility of reverse
causality, instrument variable model with the BMI of mother and its square as
exogenous measures for overweight status was evaluated. Two stage analyses,
however, revealed that overweight status was not an endogenous variable. Conse-
quently, association between obesity and depression/anxiety was evaluated using
multivariate logistic regression. The risk of increased depression/anxiety expendi-
tures was examined using a two part expenditure model was used. RESULTS: An
estimated 3.67 million (95% Confidence Interval (CI): 3.47-3.87) were obese/over-
weight in national weighted sample 10.34 million children and adolescents. The
incidence depression/anxiety among obese/overweight and non-overwight chil-
dren was 0.95and 1.75%, respectively. Multivariable analysis of a nationally repre-
sentative sample of children and adolescents indicated no significant association
between obese/overweight status and development of depression/anxiety [Ad-
justed Odds Ratio (AOR):0.65; 95% Confidence Interval (CI): 0.65-1.37]. In addition,
there was no increased f risk of depression/anxiety related expenditure (AOR: 1.39;
95% CI: 0.67-2.90), nor the risk of an increased amount of expenditure (t-statistic:
-0.41; P-value: 0.19) due to obesity/overweight. CONCLUSIONS: Obese/overweight
children and adolescents in this nationally representative community sample did
not have an increased likelihood of depression/anxiety. Thus, obese/overweight
children and adolescents may not always suffer from psychological distress.
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OBJECTIVES: Long-acting therapy (LAT) formulations of atypical antipsychotics
(AAPs) remove the need for dailymedication in the treatment of schizophrenia and
may improve outcomes. Little is known about LAT AAP use during inpatient ad-
missions. This study identifies factors associated with LAT AAP use among inpa-
tients with schizophrenia. METHODS: A retrospective analysis (2007-2010) of the
Health Facts® database (Cerner Corp., Kansas City, MO) identified adult patients
with a primary discharge diagnosis of schizophrenia and1 order for AAP. Factors
examined included demographic, clinical, and treatment setting characteristics. A
bootstrapping algorithmwithmultilevel (hierarchical) logistic regressionwas used
to identify factors most strongly associated with LAT AAP exposure. RESULTS: A
total of 3230 admissions met inclusion criteria; 217 had LAT AAP exposure. Before
regression adjustment, key factors with a significantly greater likelihood of LAT
AAP use included receiving oral risperidone (85.3% vs 35.0%, p0.001) and being
treated in a facility with500 beds (48.9% vs 31.5%, p0.001). Negative associations
included Caucasian race (47.9% vs 55.4%, p0.033), receiving most other oral AAPs
(varies by agent), and being treated in a facility with 500 beds (varies by categor-
ical size). Factors not significantly associatedwith LATAAP use included age, use of
first-generation antipsychotics, urgent admission, and treatment in a teaching fa-
cility. The regression model had good discrimination (c-statistic  0.85); factors
associated with a greater likelihood of LAT AAP exposure were male gender
(OR1.58, p0.005), diagnosis of chronic respiratory conditions (OR1.64, p0.014),
affective disorders not meeting criteria for full mood disorder (OR1.95, p0.004),
and oral risperidone (OR11.05, p0.001). Patients using olanzapine (OR0.64,
p0.057) or antidepressants (OR0.75, p0.065) trended toward not receiving LAT
AAP. CONCLUSIONS: LAT AAP use in the inpatient setting was related to gender,
certain chronic conditions, specific AAP and antidepressant use, and facility size.
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OBJECTIVES: Several stimulant and non-stimulant medications are indicated and
used alone or in combination to treat attention deficit hyperactivity disorder
(ADHD). Little is known about polypharmacy prevalence and predictors in this
population. The objective of this analysis was to describe ADHD medication utili-
zation patterns focusing on combination versus monotherapy.METHODS: Health
insurance claims from Thomson Reuters MarketScan Commercial Database were ana-
lyzed for patients with an ADHD diagnosis (ICD-9 314.0x). Patients included were
age6 as of January 2010, continuously enrolled July 2009 through December 2010,
and with a 2010 ADHD medication claim. Medication utilization was measured at
the patient-month level during 2010. Generalized-estimating equations were used
to account for within-patient correlation between months. Demographic and clin-
ical predictors were explored with atomoxetine (ATX), long-acting stimulants
(LAS), and alpha-2-adrenergic agents (A2A). RESULTS: ADHD patients (n268,172)
were primarily age 6-17 years old (57.9%) andmale (61.2%). ADHDwith hyperactiv-
itywas present in 14.2%.Of all treatment-months, 10.3%were combination therapy
(more than one ADHD medication class in same month). Short-acting stimulants
and A2A agents had the highest combination use (45.3%, 54.0% respectively). ATX,
LAS, intermediate-acting stimulants, and prodrug stimulants had the lowest per-
centage combination use (17.9%, 13.6%, 21.8%, 9.9% respectively), ATX combination
therapy was less in older patients (age 18 adjusted odds ratios [AOR] between
0.332-0.829), LAS agents were more frequently used (ages 18-44 AOR 1.079-1.457)
and A2A had no association (age 25 AOR 0.699-1.083). Females were less likely to
use combination therapy. Hyperactivity was associated with combination therapy
in all three models. Tics/Tourettes was associated with combination therapy for
ATX and LAS. CONCLUSIONS: Combination therapy rates differed by medication
class, as did the demographic and clinical characteristics that significantly pre-
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